A third line of in vivo evidence comes from autoimmunity disorders in which patients have developed anti-CaR antibodies that either inhibit [44] or activate [43] CaR and thereby produce clinical manifestations resembling FHH or ADH, respectively. Here, CASR is linked to familial hypocalciuric hypercalcemia.